Skip to main navigation Skip to main content

Clin Mol Hepatol : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

2
results for

"Young Soo Park"

Article category

Keywords

Publication year

"Young Soo Park"

Original Articles

Steatotic liver disease

Effect of vitamin E in nonalcoholic fatty liver disease with metabolic syndrome: A propensity score-matched cohort study
Gi Hyun Kim, Jung Wha Chung, Jong Ho Lee, Kyeong Sam Ok, Eun Sun Jang, Jaihwan Kim, Cheol Min Shin, Young Soo Park, Jin-Hyeok Hwang, Sook-Hyang Jeong, Nayoung Kim, Dong Ho Lee, Jin-Wook Kim
Clin Mol Hepatol 2015;21(4):379-386.
Published online December 24, 2015
DOI: https://doi.org/10.3350/cmh.2015.21.4.379
Background/Aims

Vitamin E improves the biochemical profiles and liver histology in nonalcoholic steatohepatitis, but the role of vitamin E is not clearly defined in the management of nonalcoholic fatty liver disease (NAFLD) which includes both simple steatosis and steatohepatitis. Co-morbid metabolic syndrome increases the probability of steatohepatitis in NAFLD. In this study, we aimed to determine the short-term effects of vitamin E and off-treatment durability of response in a propensity-score matched cohort of NAFLD patients with metabolic syndrome.

Methods

A retrospective cohort was constructed by retrieving 526 consecutive NAFLD patients from the electronic medical record data warehouse of a tertiary referral hospital in South Korea. Among them, 335 patients (63.7%) had metabolic syndrome and were eligible for vitamin E therapy. In order to assess the effect of vitamin E, propensity score matching was used by matching covariates between control patients (n=250) and patients who received vitamin E (n=85).

Results

The PS-matched vitamin E group (n=58) and control group (n=58) exhibited similar baseline metabolic profiles. After 6 months of vitamin E therapy, the mean ALT levels decreased significantly compared to PS-matched control (P<0.01). The changes in metabolic profiles (body weight, lipid and glucose levels) did not differ between control and vitamin E groups during the study period.

Conclusions

Short-term vitamin E treatment significantly reduces ALT levels in NAFLD patients with metabolic syndrome, but metabolic profiles are not affected by vitamin E.

Citations

Citations to this article as recorded by  Crossref logo
  • Pathological features of non-alcoholic steatohepatitis in a pediatric patient with heterozygous familial hypobetalipoproteinemia: A case report
    Kiwako Miyamoto, Sonoko Kondo, Takeo Kondo, Ryou Ishikawa, Ryosuke Tani, Tomoko Inoue, Keiji Matsunaga, Tetsuo Minamino, Takashi Kusaka
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • Modulatory impact of wheat metabolome on Wnt/β-catenin signaling pathway in an obesity-induced rat model
    Noha El-Zeiny, Rasha Hanafi, Heba Handoussa
    Food Bioscience.2025; 68: 106508.     CrossRef
  • Vitamin E and Non-alcoholic Fatty Liver Disease: Investigating the Evidence Through a Systematic Review
    Mahlet Abera, Suchith B Suresh, Aparna Malireddi, Sruthi Boddeti, Khutaija Noor, Mehwish Ansar, Iana Malasevskaia
    Cureus.2024;[Epub]     CrossRef
  • Allium sativum: A potential natural compound for NAFLD prevention and treatment
    Parham Mardi, Reza Kargar, Ramina Fazeli, Mostafa Qorbani
    Frontiers in Nutrition.2023;[Epub]     CrossRef
  • Exploring the Impact of Nutrition on Non-Alcoholic Fatty Liver Disease Management: Unveiling the Roles of Various Foods, Food Components, and Compounds
    Marcin Kosmalski, Rafał Frankowski, Kacper Deska, Monika Różycka-Kosmalska, Tadeusz Pietras
    Nutrients.2023; 15(13): 2838.     CrossRef
  • Effect of Vitamin E on Clinical Outcomes in Patients With Non-alcoholic Fatty Liver Disease: A Meta-Analysis
    Jithin Karedath, Hiba Javed, Fatima Ahsan Talpur, Bihari Lal, Anmol Kumari, Husam Kivan, Venkata Anirudh Chunchu, Shamsha Hirani
    Cureus.2022;[Epub]     CrossRef
  • Current innovations in nutraceuticals and functional foods for intervention of non-alcoholic fatty liver disease
    Mengyao Zhao, Shumin Chen, Xiaoguo Ji, Xin Shen, Jiangshan You, Xinyi Liang, Hao Yin, Liming Zhao
    Pharmacological Research.2021; 166: 105517.     CrossRef
  • Can vitamin E supplementation affect obesity indices? A systematic review and meta-analysis of twenty-four randomized controlled trials
    Mohammad Reza Emami, Sanaz Jamshidi, Meysam Zarezadeh, Masoud Khorshidi, Beheshteh Olang, Zohreh Sajadi Hezaveh, Mohammadhassan Sohouli, Naheed Aryaeian
    Clinical Nutrition.2021; 40(5): 3201.     CrossRef
  • Use of a bioengineered antioxidant in mouse models of metabolic syndrome
    Deric M. Griffin, Brittany R. Bitner, Zachary Criss Ii, Daniela Marcano, Jacob M. Berlin, Thomas A. Kent, James M. Tour, Susan L. Samson, Robia G. Pautler
    Expert Opinion on Investigational Drugs.2020; 29(2): 209.     CrossRef
  • VII. The Evidence of Pharmacologic Treatment for NASH
    Masashi Yoneda
    Nihon Naika Gakkai Zasshi.2020; 109(1): 56.     CrossRef
  • Gamma-tocopherol ameliorates hyperglycemia-induced hepatic inflammation associated with NLRP3 inflammasome in alloxan-induced diabetic mice
    Heaji Lee, Yunsook Lim
    Nutrition Research and Practice.2019; 13(5): 377.     CrossRef
  • Effect of vitamin E in non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomised controlled trials
    Iram Amanullah, Yusra Habib Khan, Iqraa Anwar, Aqsa Gulzar, Tauqeer Hussain Mallhi, Ahsan Aftab Raja
    Postgraduate Medical Journal.2019; 95(1129): 601.     CrossRef
  • Haptoglobin Genotype and Vitamin E Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design
    Shufei Zang, Jin Chen, Yu Song, Lang Bai, Jinjun Chen, Xiaoling Chi, Fangping He, Huiping Sheng, Jing Wang, Shilong Xie, Wen Xie, Yongfeng Yang, Jing Zhang, Minghua Zheng, Zhengsheng Zou, Bingyuan Wang, Junping Shi
    Advances in Therapy.2018; 35(2): 218.     CrossRef
  • An Overview of Novel Dietary Supplements and Food Ingredients in Patients with Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease
    Priscila Silva Figueiredo, Aline Inada, Melina Ribeiro Fernandes, Daniela Granja Arakaki, Karine Freitas, Rita Avellaneda Guimarães, Valter Aragão do Nascimento, Priscila Aiko Hiane
    Molecules.2018; 23(4): 877.     CrossRef
  • 17,802 View
  • 190 Download
  • 17 Web of Science
  • Crossref
Serum prohepcidin levels in chronic hepatitis C, alcoholic liver disease, and nonalcoholic fatty liver disease
Sang Hyub Lee, Sook-Hyang Jeong, Young Soo Park, Jin-Hyeok Hwang, Jin-Wook Kim, Nayoung Kim, Dong Ho Lee
Korean J Hepatol 2010;16(3):288-294.
Published online September 30, 2010
DOI: https://doi.org/10.3350/kjhep.2010.16.3.288
Background/Aims

Patients with various chronic liver diseases frequently have increased body iron stores. Prohepcidin is an easily measurable precursor of hepcidin, which is a key regulator of iron homeostasis. This study investigated the serum prohepcidin levels in patients with various chronic liver diseases with various etiologies.

Methods

Serum prohepcidin levels were measured in patients with chronic hepatitis C (CH-C) (n=28), nonalcoholic fatty liver disease (NAFLD) (n=24), and alcoholic liver disease (ALD) (n=22), and in healthy controls (n=25) using commercial ELISA. Serum interleukin 6 (IL-6) levels and blood iron indices were also measured.

Results

The serum levels of both prohepcidin and IL-6 were significantly higher in CH-C patients than in healthy controls, and there was a positive correlation between the IL-6 and prohepcidin levels (r=0.505, p=0.020). The prohepcidin levels in ALD patients did not differ from those in controls, despite their significantly elevated IL-6 levels. There was a tendency for a negative correlation between serum prohepcidin levels and transferrin saturation in ALD patients (r=-0.420, p=0.051). Neither prohepcidin nor IL-6 was significantly elevated in the NAFLD group, despite the presence of elevated serum iron and ferritin levels.

Conclusions

The role of prohepcidin may differ in different human liver diseases. In the setting of CH-C, both the serum prohepcidin and IL-6 levels were significantly elevated and were positively correlated with each other.

Citations

Citations to this article as recorded by  Crossref logo
  • Hemoglobin and Its Z Score Reference Intervals in Febrile Children: A Cohort Study of 98,572 Febrile Children
    Chu-Yin Cheng, Ting-Hsuan Hsu, Ya-Ling Yang, Ying-Hsien Huang
    Children.2023; 10(8): 1402.     CrossRef
  • A Study of Changes in Prohepcidin and Iron Levels in Patients with Liver Transplant and Chronic Viral Hepatitis
    Özlem ÖZDEMİR, Mesut AKARSU, Pınar TOSUN TAŞAR, Faize YÜKSEL, Aylin BACAKOĞLU, Tarkan ÜNEK, Fatih DEMİRKAN, Sedat KARADEMİR
    Namık Kemal Tıp Dergisi.2023; 11(1): 66.     CrossRef
  • Liver Sinusoidal Endothelial Cells at the Crossroad of Iron Overload and Liver Fibrosis
    Sara Petrillo, Marta Manco, Fiorella Altruda, Sharmila Fagoonee, Emanuela Tolosano
    Antioxidants & Redox Signaling.2021; 35(6): 474.     CrossRef
  • Inflammatory and cardiovascular diseases biomarkers in chronic hepatitis C virus infection: A review
    Ahmed Babiker, Mohamed Hassan, Safwan Muhammed, Gregory Taylor, Bhawna Poonia, Anoop Shah, Shashwatee Bagchi
    Clinical Cardiology.2020; 43(3): 222.     CrossRef
  • C-Reactive Protein Concentration Can Help to Identify Bacteremia in Children Visiting the Emergency Department: A Single Medical Center Experience
    I-Min Chiu, Ying-Hsien Huang, Chih-Min Su, Chia-Te Kung, Chao-Jui Li, Chih-Ho Chen, Kuo-Su Tang, Kuang-Che Kuo
    Pediatric Emergency Care.2020; 36(6): 291.     CrossRef
  • Relationship of serum haemojuvelin and hepcidin levels with iron level and erythropoietin requirement in prevalent hepatitis C virus positive haemodialysis patients
    Heba W. El Said, Khaled H. Abou Seif, Yasser S. Ahmed, Hesham A. Abou Elleil, Tamer W. El Said, Maha A. Behairy, Mohamed M. Mohamed, Fatma A. Ahmed
    Nephrology.2018; 23(4): 323.     CrossRef
  • Anemia in Kawasaki Disease: Hepcidin as a Potential Biomarker
    Ying-Hsien Huang, Ho-Chang Kuo
    International Journal of Molecular Sciences.2017; 18(4): 820.     CrossRef
  • Hepcidin in morbidly obese women with non-alcoholic fatty liver disease
    Teresa Auguet, Gemma Aragonès, Alba Berlanga, Salomé Martínez, Fàtima Sabench, Jessica Binetti, Carmen Aguilar, José Antonio Porras, Alicia Molina, Daniel Del Castillo, Cristóbal Richart, Pavel Strnad
    PLOS ONE.2017; 12(10): e0187065.     CrossRef
  • Alcoholic liver disease: Clinical and translational research
    Manuela G. Neuman, Stephen Malnick, Yaakov Maor, Radu M. Nanau, Ehud Melzer, Peter Ferenci, Helmut K. Seitz, Sebastian Mueller, Haim Mell, Didier Samuel, Lawrence B. Cohen, Kusum K. Kharbanda, Natalia A. Osna, Murali Ganesan, Kyle J. Thompson, Iain H. McK
    Experimental and Molecular Pathology.2015; 99(3): 596.     CrossRef
  • The Wide and Complex Field of NAFLD Biomarker Research: Trends
    Erika Wichro, Tanja Macheiner, Jasmin Schmid, Barbara Kavsek, Karine Sargsyan
    ISRN Hepatology.2014; 2014: 1.     CrossRef
  • Serum hepcidin levels and iron metabolism in obese children with and without fatty liver: case–control study
    Fatih Demircioğlu, Gökhan Görünmez, Emine Dağıstan, Sevil Bilir Göksügür, Mervan Bekdaş, Mehmet Tosun, Betül Kızıldağ, Erol Kısmet
    European Journal of Pediatrics.2014; 173(7): 947.     CrossRef
  • Serum prohepcidin concentrations in rheumatoid arthritis and its relation to disease activity
    Ahmad Emerah, Samah F. Abbas, Heba F. Pasha
    Egyptian Rheumatology and Rehabilitation.2014; 41(3): 130.     CrossRef
  • Lower serum prohepcidin levels associated with lower iron and erythropoietin requirements in hemodialysis patients with chronic hepatitis C
    Yasar Caliskan, Berna Yelken, Abdullah Ozkok, Numan Gorgulu, Halil Yazici, Aysegul Telci, Alaattin Yildiz
    BMC Nephrology.2012;[Epub]     CrossRef
  • Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations
    James E. Nelson, Elizabeth M. Brunt, Kris V. Kowdley
    Hepatology.2012; 56(5): 1730.     CrossRef
  • Serum prohepcidin levels are potential prognostic markers in patients with multiple myeloma
    KOUICHI HARAGUCHI, HIROFUMI UTO, NOBUHITO OHNOU, MASAHITO TOKUNAGA, MAYUMI TOKUNAGA, ATAE UTSUNOMIYA, SHUICHI HANADA, HIROHITO TSUBOUCHI
    Experimental and Therapeutic Medicine.2012; 4(4): 581.     CrossRef
  • 10,188 View
  • 51 Download
  • Crossref